Cascade Biotechnology INC.Cascade Biotechnology INC.
  • Home
  • Announcements 2022
  • Complement Therapeutics General Overview
  • Complement Therapeutics Disease Indications
  • Pipeline
  • Alzheimer's disease
  • Schizophrenia
  • Multiple Sclerosis-Autoimmune
  • Neuromyelitis Optica-Autoimmune
  • Myasthenia Gravis-Autoimmune
  • Amyotrophic Lateral Sclerosis (ALS) Autoimmune
  • Age-Related Macular Degeneration
  • Paroxysmal Nocturnal Hemoglobinuria
  • Cutaneous Squamous Cell Carcinoma (cSCC)
  • Cardiac and Myocardial Ischemia
  • Atypical Hemolytic Uremic Syndrome (aHUS)
  • Technology
  • Staff Publications
  • Funding
  • Scientific Advisory Board (SAB)
  • Management
  • Images  
  • Complement Depletion and Disease Models
  • Human C3-1496 Potential Immunogenicity
  • C3b Crystal Structure Allows Amino Acid Changes that Stabilize C3 (sC3)
  • sC3 Designed for Increased Catalytic Efficiency, Potency, Better pK Properties
  • sC3 Depletes Complement More Potently than CVF
  • sC3 is More Stable in Serum
  • sC3 Resists Degradation
  • sC3 Gene Therapy Strategy
  • sC3 Gene Therapy Sub-Retinal Injections of Viral Particles
  • sC3 Gene Therapy Coding Sequence and HEK293 Co-Transfection
  • sC3 Gene Therapy, Vector Design Completed, Lentivirus Synthesized, RPE Cells Infected
  • sC3 Cascade Intellectual Property
  • Gallery
  • What's Hot in Complement 2020-2021
  •  
  •  
  •  
  •  
  •  
 
Cascade Biotechnology INC.Cascade Biotechnology INC.
  •  
  •  
  •  
  •  
  •  
  • Home
  • Announcements 2022
  • Complement Therapeutics General Overview
  • Complement Therapeutics Disease Indications
  • Pipeline
  • Alzheimer's disease
  • Schizophrenia
  • Multiple Sclerosis-Autoimmune
  • Neuromyelitis Optica-Autoimmune
  • Myasthenia Gravis-Autoimmune
  • Amyotrophic Lateral Sclerosis (ALS) Autoimmune
  • Age-Related Macular Degeneration
  • Paroxysmal Nocturnal Hemoglobinuria
  • Cutaneous Squamous Cell Carcinoma (cSCC)
  • Cardiac and Myocardial Ischemia
  • Atypical Hemolytic Uremic Syndrome (aHUS)
  • Technology
  • Staff Publications
  • Funding
  • Scientific Advisory Board (SAB)
  • Management
  • Images  
  • Complement Depletion and Disease Models
  • Human C3-1496 Potential Immunogenicity
  • C3b Crystal Structure Allows Amino Acid Changes that Stabilize C3 (sC3)
  • sC3 Designed for Increased Catalytic Efficiency, Potency, Better pK Properties
  • sC3 Depletes Complement More Potently than CVF
  • sC3 is More Stable in Serum
  • sC3 Resists Degradation
  • sC3 Gene Therapy Strategy
  • sC3 Gene Therapy Sub-Retinal Injections of Viral Particles
  • sC3 Gene Therapy Coding Sequence and HEK293 Co-Transfection
  • sC3 Gene Therapy, Vector Design Completed, Lentivirus Synthesized, RPE Cells Infected
  • sC3 Cascade Intellectual Property
  • Gallery
  • What's Hot in Complement 2020-2021

sC3 Gene Therapy Coding Sequence and HEK293 Co-Transfection


  •  
  •  
  •  
  • Home
  • Announcements 2022
  • Complement Therapeutics General Overview
  • Complement Therapeutics Disease Indications
  • Pipeline
  • Alzheimer's disease
  • Schizophrenia
  • Multiple Sclerosis-Autoimmune
  • Neuromyelitis Optica-Autoimmune
  • Myasthenia Gravis-Autoimmune
  • Amyotrophic Lateral Sclerosis (ALS) Autoimmune
  • Age-Related Macular Degeneration
  • Paroxysmal Nocturnal Hemoglobinuria
  • Cutaneous Squamous Cell Carcinoma (cSCC)
  • Cardiac and Myocardial Ischemia
  • Atypical Hemolytic Uremic Syndrome (aHUS)
  • Technology
  • Staff Publications
  • Funding
  • Scientific Advisory Board (SAB)
  • Management
  • Complement Depletion and Disease Models
  • Human C3-1496 Potential Immunogenicity
  • C3b Crystal Structure Allows Amino Acid Changes that Stabilize C3 (sC3)
  • sC3 Designed for Increased Catalytic Efficiency, Potency, Better pK Properties
  • sC3 Depletes Complement More Potently than CVF
  • sC3 is More Stable in Serum
  • sC3 Resists Degradation
  • sC3 Gene Therapy Strategy
  • sC3 Gene Therapy Sub-Retinal Injections of Viral Particles
  • sC3 Gene Therapy Coding Sequence and HEK293 Co-Transfection
  • sC3 Gene Therapy, Vector Design Completed, Lentivirus Synthesized, RPE Cells Infected
  • sC3 Cascade Intellectual Property
  • Gallery
  • What's Hot in Complement 2020-2021
Copyright © 2023 All rights reserved - Cascade Biotechnology INC.
  •  609-610-3935
  •   edholland@cenoxsys.com
  •   1 Deer Park Dr., Suite D5, Princeton Corporate Plaza, Monmouth Junction, NJ 08852
  • Google Maps
  • Waze
  • Moovit
  • Moovit
  •  
  •  
  •